IBYME   02675
INSTITUTO DE BIOLOGIA Y MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
artículos
Título:
Metformin regulates ovarian angiogenesis and follicular development in a female Polycystic Ovary Syndrome rat model
Autor/es:
DI PIETRO M; PARBORELL F,; IRUSTA G.; PASCUALI N; BAS D; BIANCHI MS; TESONE M; ABRAMOVICH D
Revista:
ENDOCRINOLOGY
Editorial:
ENDOCRINE SOC
Referencias:
Año: 2015 vol. 156 p. 1453 - 1463
ISSN:
0013-7227
Resumen:
Polycystic ovary syndrome (PCOS) is a frequent pathology that affects more than 5% of women ofreproductive age. Among other heterogeneous symptoms, PCOS is characterized by abnormalitiesin angiogenesis. Metformin has been introduced in the treatment of PCOS to manage insulinresistance and hyperglycemia. Besides its metabolic effects, metformin has been shown to improveovulation, pregnancy and live birth rates in PCOS patients. In the present study, we used a dehydroepiandrosterone-inducedPCOSrat model to analyze the effect of metformin administrationonovarian angiogenesis.Wefound that metformin was able to restore the increased levels of vascularendothelial growth factor, angiopoietin (ANGPT)1, and ANGPT1/ANGPT2 ratio and the decreasedlevels of platelet-derived growth factor B and platelet-derived growth factor D observed in thedehydroepiandrosterone-treated rats. These effects could take place, at least in part, through adecrease in the levels of serum insulin. We also found an improvement in follicular development,with a lower percentage of small follicles and cysts and a higher percentage of antral follicles andcorpora lutea after metformin administration. The improvement in ovarian angiogenesis is likelyto restore the accumulation of small follicles observed in PCOS rats and to reduce cyst formation,thus improving follicular development and the percentage of corpora lutea. These results opennew insights into the study of metformin action not only in glucose metabolism but also in ovariandysfunction in PCOS women.